ARROWHEAD PHARMACEUTICALS, INC. (ARWR)

39 0.03 (0.08%)

As of 2025-10-16 20:25:26 EST

Arrowhead Pharmaceuticals, Inc. is a publicly traded biopharmaceutical company based in Pasadena, California. Arrowhead’s products in development act through RNA interference (RNAi) mechanisms of action. The company focuses on treatments for hepatitis B, liver disease associated with alpha 1-antitrypsin deficiency and cardiovascular disease.

Traded asNasdaq: ARWR
ISINUS04280A1007
CIK0000879407
LEI549300O3CSB8T7OZ3D66
EIN460408024
SectorBiotechnology
IndustryPharmaceutical Preparations
CEOChristopher Anzalone, Ph.D.
Employees376
Fiscal Year End0930
Address177 E COLORADO BLVD, PASADENA, CA, 91105
Phone626-696-4702
Websitehttp://arrowheadpharma.com
Stock Quotes
trading_symbolregistrant_nametimepricechangepercentage_change
ARWRARROWHEAD PHARMACEUTICALS, INC.2025-10-16 20:25:26390.030.08
This is a preview of the latest data. Subscribe to access the full data.
Company Information
trading_symbolcentral_index_keyregistrant_nameisin_numberlei_numberein_numberexchangesic_codesic_descriptionfiscal_year_endstate_of_incorporationaddress_streetaddress_cityaddress_stateaddress_zip_codeaddress_countryaddress_country_codephone_numbermailing_addressbusiness_addressformer_nameindustryfounding_datechief_executive_officernumber_of_employeeswebsitemarket_capshares_issuedshares_outstandingdescriptionupdate_time
ARWR0000879407ARROWHEAD PHARMACEUTICALS, INC.US04280A1007549300O3CSB8T7OZ3D66460408024Nasdaq2834Pharmaceutical Preparations0930DE177 E COLORADO BLVDPASADENACA91105UNITED STATESUS626-696-4702177 E COLORADO BLVD, PASADENA, CA, 91105177 E COLORADO BLVD, PASADENA, CA, 91105ARROWHEAD RESEARCH CORPBiotechnology2004-01-01Christopher Anzalone, Ph.D.376http://arrowheadpharma.com3,000,000,000138,144,000138,257,550Arrowhead Pharmaceuticals, Inc. is a publicly traded biopharmaceutical company based in Pasadena, California. Arrowhead’s products in development act through RNA interference (RNAi) mechanisms of action. The company focuses on treatments for hepatitis B, liver disease associated with alpha 1-antitrypsin deficiency and cardiovascular disease.2025-10-10 20:13:26
This is a preview of the latest data. Subscribe to access the full data.
ARWR Stock Price (End-of-Day)
This is a preview of the latest data. Subscribe to access the full data.
ARWR Stock Price (1-Minute)
This is a preview of the latest data. Subscribe to access the full data.
Market Cap
Fiscal YearMarket CapChange In Market CapPercentage Change In Market CapShares OutstandingChange In Shares OutstandingPercentage Change In Shares Outstanding
20243,000,000,000700,000,00030.4348124,434,44217,002,23215.826
20232,300,000,000-1,800,000,000-43.9024107,432,2101,426,4881.3457
20224,100,000,000-1,800,000,000-30.5085106,005,7221,480,0141.4159
This is a preview of the latest data. Subscribe to access the full data.
Executive Compensation
Executive NameExecutive PositionFiscal YearSalaryBonusStock AwardsIncentive Plan CompensationOther CompensationTotal Compensation
Javier San MartinChief Medical Officer2024260,52902,589,7500606,2853,456,564
Christopher AnzaloneChief Executive Officer, President2024951,012010,319,0001,152,0001,46112,423,473
Kenneth MyszkowskiChief Financial Officer2024592,36902,589,750314,49615,7613,512,376
Patrick O’BrienChief Operating Officer, General Counsel2024605,25902,935,050378,00015,2613,933,570
Tracie OliverChief Commercial Officer2024484,06502,589,75002,9653,076,780
This is a preview of the latest data. Subscribe to access the full data.
Employee Count
Fiscal YearEmployee Count
2024609
2023525
2022397
This is a preview of the latest data. Subscribe to access the full data.
Income Statements
Fiscal Year202420232022
Revenue—240,735,000243,231,000
Cost Of Revenue———
Gross Profit———
Research And Development Expenses—353,188,000297,307,000
General And Administrative Expenses—92,549,000124,431,000
Operating Expenses—445,737,000421,738,000
Operating Income—-205,002,000-178,507,000
Net Income—-205,275,000-176,063,000
Earnings Per Share Basic—-1.92-1.67
Earnings Per Share Diluted—-1.92-1.67
Weighted Average Shares Outstanding Basic—106,750,000105,426,000
Weighted Average Shares Outstanding Diluted—106,750,000105,426,000
This is a preview of the latest data. Subscribe to access the full data.
Balance Sheet Statements
Fiscal Year202420232022
Cash And Cash Equivalents—110,891,000108,005,000
Marketable Securities Current—00
Accounts Receivable—01,410,000
Inventories———
Non Trade Receivables———
Other Assets Current—7,082,00020,204,000
Total Assets Current—419,521,000405,299,000
Marketable Securities Non Current—0105,872,000
Property Plant And Equipment—290,262,000110,297,000
Other Assets Non Current—210,000218,000
Total Assets Non Current—346,031,000286,640,000
Total Assets—765,552,000691,939,000
Accounts Payable—35,866,0002,868,000
Deferred Revenue—866,00074,099,000
Short Term Debt———
Other Liabilities Current—435,00046,856,000
Total Liabilities Current—105,456,000138,850,000
Long Term Debt———
Other Liabilities Non Current———
Total Liabilities Non Current—372,934,000134,750,000
Total Liabilities—478,390,000273,600,000
Common Stock—200,000198,000
Retained Earnings—-1,026,030,000-820,755,000
Accumulated Other Comprehensive Income—-3,222,000-136,000
Total Shareholders Equity—271,343,000398,520,000
This is a preview of the latest data. Subscribe to access the full data.
Cash Flow Statements
Fiscal Year202420232022
Depreciation And Amortization—12,493,00010,421,000
Share Based Compensation Expense—78,130,000120,893,000
Other Non Cash Income Expense———
Change In Accounts Receivable—-1,410,000-8,845,000
Change In Inventories———
Change In Non Trade Receivables———
Change In Other Assets———
Change In Accounts Payable—32,998,000-6,589,000
Change In Other Liabilities—065,000
Cash From Operating Activities—-153,890,000-136,131,000
Purchases Of Marketable Securities—246,141,000223,391,000
Sales Of Marketable Securities—326,723,000270,751,000
Acquisition Of Property Plant And Equipment—176,737,00052,777,000
Acquisition Of Business———
Other Investing Activities———
Cash From Investing Activities—-96,155,000-5,417,000
Tax Withholding For Share Based Compensation———
Payments Of Dividends———
Issuance Of Common Stock——0
Repurchase Of Common Stock———
Issuance Of Long Term Debt———
Repayment Of Long Term Debt———
Other Financing Activities———
Cash From Financing Activities—253,053,00065,186,000
Change In Cash—3,008,000-76,362,000
Cash At End Of Period—110,891,000108,005,000
Income Taxes Paid—0-2,000
Interest Paid—00
This is a preview of the latest data. Subscribe to access the full data.
Key Metrics
Fiscal Year202420232022
Earnings Per Share—-1.92-1.67
Price To Earnings Ratio—-13.9948-19.7904
Earnings Growth Rate—14.970122.7941
Price Earnings To Growth Ratio—-0.9349-0.8682
Book Value Per Share—2.693.9681
Price To Book Ratio—9.98878.329
Ebitda—-174,456,000-165,644,000
Enterprise Value———
Dividend Yield———
Dividend Payout Ratio———
Debt To Equity Ratio———
Capital Expenditures—192,458,00072,043,000
Free Cash Flow—-346,348,000-208,174,000
Return On Equity—-0.7565-0.4418
One Year Beta1.56681.38841.7642
Three Year Beta1.60121.5441.3184
Five Year Beta1.33941.44941.484
This is a preview of the latest data. Subscribe to access the full data.
Insider Transactions
Insider NameRelationship To IssuerTransaction DateAmount Of SecuritiesAcquired Or DisposedSecurities Owned Following Transaction
Hamilton James CChief Medical Officer2025-10-0120,000D212,122
Hamilton James CChief Medical Officer2025-09-1215,000D232,122
Hamilton James CChief Medical Officer2025-09-0215,000D247,122
Hamilton James CChief Medical Officer2025-08-159,389D262,122
Hamilton James CChief Medical Officer2025-08-13611D271,511
This is a preview of the latest data. Subscribe to access the full data.
House Trading
Name Of Reporting PersonReport DateStateTransaction TypeTransaction DateOwner TypeAmount
Daniel Goldman2023-02-24NY10Sale2023-01-31—$1,001 - $15,000
This is a preview of the latest data. Subscribe to access the full data.
Institutional Holdings
Investor NamePeriod Of ReportMarket ValueAmount Of SecuritiesPrice Per Security
Signature Resources Capital Management, LLC2025-09-306,20818034.4889
CWM, LLC2025-09-30420,00012,17934.4856
World Investment Advisors2025-09-30475,16913,77734.49
PRIVATE TRUST CO NA2025-09-3010,86431534.4889
YOUSIF CAPITAL MANAGEMENT, LLC2025-09-301,502,59143,56634.49
This is a preview of the latest data. Subscribe to access the full data.
Mutual Fund Holdings
Registrant NamePeriod Of ReportFund NameFund SymbolAmount Of UnitsValue In UsdPercentage Value Compared To Assets
TRUST FOR PROFESSIONAL MANAGERS2025-08-31Column Small Cap Select FundCFSSX73,5251,619,755.750.1128
Advisors' Inner Circle Fund III2025-07-31I SharesKCXIX5368,468.80.0035
INVESCO EXCHANGE-TRADED FUND TRUST2025-07-31Invesco RAFI US 1500 Small-Mid ETFPRFZ75,2811,189,439.80.0502
Global X Funds2025-07-31Global X Russell 2000 ETFRSSL61,751975,665.80.0742
BNY MELLON INDEX FUNDS, INC.2025-07-31Class IDISIX78,8081,245,166.40.1483
This is a preview of the latest data. Subscribe to access the full data.